Various new biomarkers, such as PMEPAI and SKIL, have been identified and tested in preclinical ex vivo models in which HCC specimens have been treated with TGF-β under “in vitro” conditions [180]. This evidence concerns the gene TGFB1 and hepatocellular carcinoma.